Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock. On April 1, 2026, he sold a total of 15,000 shares of common stock in two transactions, at weighted average prices of $49.20 and $49.92 per share.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Cameron directly holds 627,540 shares of Spyre Therapeutics common stock, including 116,168 shares that vest in monthly installments through November 2026, contingent on his continued service.
Spyre Therapeutics, Inc. Chief Medical Officer Sloan Sheldon exercised stock options and sold the resulting shares. On this Form 4, Sheldon exercised options to acquire 7,958 shares of common stock at an exercise price of $21.66 per share and immediately sold all 7,958 shares at $50.00 per share.
The filing notes that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025, indicating the timing was set in advance rather than being a discretionary market-timing decision.
Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales. On April 1, 2026, he exercised stock options to acquire 7,500 shares of common stock at an exercise price of $14.50 per share, fully using the remaining options covered in this filing.
On the same date, he sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98 in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 97,994 shares of common stock, including 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Spyre Therapeutics Inc Common Stock. The amendment explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately; the filing states the reported holdings include securities in the form of rights.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported option exercises and related share sales. He exercised a stock option for 2,500 shares of common stock at $14.50 per share through a derivative conversion. On the same date, he sold a total of 2,500 shares of common stock in open-market transactions at weighted average prices of $40.56 and $41.66 per share under a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly held 97,994 shares of common stock, which the filing notes include 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The stock option originally covered 404,857 shares, with vesting over several years.
Spyre Therapeutics, Inc.'s Chief Executive Officer, Cameron Turtle, reported selling a total of 15,000 shares of common stock in open-market transactions on March 2, 2026. The sales, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, were completed in two trades at weighted average prices of $41.73 and $42.49, each reflecting multiple executions within stated price ranges. Following these transactions, the CEO directly holds 642,540 shares of common stock, which includes 130,683 shares scheduled to vest in monthly installments through November 2026, subject to continued service.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing proposed sales of 60,000 common shares of SYRE, linked to previously exercised stock options dated 06/15/2023. The filing records completed 10b5-1 sales of 15,000 shares on 01/02/2026 and 15,000 shares on 02/02/2026, with proceeds of $460,114.50 and $492,069.00, respectively.